Skip to main content
      Primary CNS vasculitis: what else causes vessel wall enhancement on dedicated brain MRI?

      From Dr. Hajj-Ali https://t.co

      Brian Jaros, MD Dr_Brian_MD

      1 week 4 days ago
      Primary CNS vasculitis: what else causes vessel wall enhancement on dedicated brain MRI? From Dr. Hajj-Ali https://t.co/v5ZtyezX3x
      At the Global Rheum Summit, patients called for care that values people, not just disease.

      ✅ Respect lived experience

      Jiha Lee JihaRheum

      1 week 4 days ago
      At the Global Rheum Summit, patients called for care that values people, not just disease. ✅ Respect lived experience ✅ Enable shared decisions ✅ Support education & coordination of care decisions. @RheumNow #ACR25
      ~1 in 6 pts with #sarcoidosis May have #cardiac involvemt

      1/3 respond to #MTX + #steroids
      Followed by repeat #PET

      Fail

      Janet Pope Janetbirdope

      1 week 4 days ago
      ~1 in 6 pts with #sarcoidosis May have #cardiac involvemt 1/3 respond to #MTX + #steroids Followed by repeat #PET Failures get 👇 #infliximab >#adalimumab 👇 #JAKi Better survival >yrs ago R heart involved ⬆️risk of MTX nonresponse #ACR25 @RheumNow @ACRheum abst#1664 #ACRbest https://t.co/kYt9JRNSVH
      In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, eithe

      David Liew drdavidliew

      1 week 4 days ago
      In case you missed it in @ACR_Journals: HCQ for 1y does not prevent RA development in people with CCP3 >2x ULN, either: - during 1y of treatment - in 2y follow-up https://t.co/gtzNiSmutb but StopRA will give us plenty of insights - data is never wasted #ACR25 ABST1674 @RheumNow https://t.co/DDZib5VGtX
      SELECT-COMPARE (upadacitinib vs adallimumab in mod-severe RA, no CV enrichment) 7y data:

      safety profiles very similar,

      David Liew drdavidliew

      1 week 4 days ago
      SELECT-COMPARE (upadacitinib vs adallimumab in mod-severe RA, no CV enrichment) 7y data: safety profiles very similar, except for: - zoster - CK rise - lymphopenia - hepatic disorder In the general RA population, no new JAKi safety signals #ACR25 ABST1676 @RheumNow https://t.co/BA2JxONGfa
      #ACR25 Please find our Day 1 Recap of the conference where we discussed our favourite abstracts and learning points 😃

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 week 4 days ago
      #ACR25 Please find our Day 1 Recap of the conference where we discussed our favourite abstracts and learning points 😃 @Janetbirdope @AurelieRheumo @RheumNow https://t.co/X125tjyqi5
      Abstract 1421: PsA and 'Brain Fog'
      Pts w/ #PsA who did not achieve Minimal Disease Activity (MDA) had higher odds of su

      Akhil Sood MD, MS AkhilSoodMD

      1 week 4 days ago
      Abstract 1421: PsA and 'Brain Fog' Pts w/ #PsA who did not achieve Minimal Disease Activity (MDA) had higher odds of subjective cognitive decline vs those with MDA 🔹 Fatigue, and to a lesser extent depression/anxiety, ↓ this associated risk @RheumNow #ACR25 https://t.co/RohwKJZDzp
      In the IMPACT trial (Abs 0855), certolizumab met its primary endpoint: <20% had an adverse pregnancy outcome (APO) am

      Akhil Sood MD, MS AkhilSoodMD

      1 week 4 days ago
      In the IMPACT trial (Abs 0855), certolizumab met its primary endpoint: <20% had an adverse pregnancy outcome (APO) among females w/ APS & prior APO. ✅ 94% live births, all survived to discharge 📈 Median GA: 37 wks (no APO) vs 31 wks (APO) @RheumNow #ACR25
      Start strong, stay strong.

      With early anti-TNF induction (vs csDMARD T2T)
      - At 5 yrs: D2T RA in <1% vs 7% (OR 0.11,

      Jiha Lee JihaRheum

      1 week 4 days ago
      Start strong, stay strong. With early anti-TNF induction (vs csDMARD T2T) - At 5 yrs: D2T RA in <1% vs 7% (OR 0.11, p=0.03) Drug-free remission 13% vs 6% (p=0.049) - At 10 yrs: more sustained remission (62% vs 45%) & fewer multi-MoA failures. @RheumNow #ACR25 Abstract #1677
      What is the secret of a VNS RCT that works in RA?
      => Implant the device!

      RESET-RA RCT Sham controlled 3mo
      Then open

      Aurelie Najm AurelieRheumo

      1 week 4 days ago
      What is the secret of a VNS RCT that works in RA? => Implant the device! RESET-RA RCT Sham controlled 3mo Then open label in active arm for 66mo 40% pts IR to >=3 bioDMARDs ACR 20 3 mo 42% vs. 19% CDAI LDA 27% vs. 11% 82% TNF IR pt had no change in treatment over 12mo 99% https://t.co/lfxa4YXUB4
      Implantable vagal stimulator led to benefit in TNF-inadequate responder RA in this sham-controlled double-blind RCT (RES

      David Liew drdavidliew

      1 week 4 days ago
      Implantable vagal stimulator led to benefit in TNF-inadequate responder RA in this sham-controlled double-blind RCT (RESET-RA study) - 82% off b/tsDMARDs at 12mo - also with benefit to control group after crossover at 3mo to an active device #ACR25 1675 @RheumNow https://t.co/yYwWCKm6HF
      Did we need a 2nd Interception RCT of HCQ in Pre-RA?

      Unsure but in any case, it does not work either

      STOPRA CCP3+>=

      Aurelie Najm AurelieRheumo

      1 week 4 days ago
      Did we need a 2nd Interception RCT of HCQ in Pre-RA? Unsure but in any case, it does not work either STOPRA CCP3+>=2 ind 71 HCQ and 74 PBO 36 months RA conversion Dr Deane's take: "probably wrong drug rather than wrong timing" #ACR25 @RheumNow #ABSTRACT1674 https://t.co/jysdo8iz7v
      New tx for IPF/autoimmune ILD, nerandomilast (PDE4Bi)

      Subgroup analysis from FIBRONEER-ILD, marginally less FVC worseni

      Mike Putman EBRheum

      1 week 4 days ago
      New tx for IPF/autoimmune ILD, nerandomilast (PDE4Bi) Subgroup analysis from FIBRONEER-ILD, marginally less FVC worsening (-65mL tx grp vs -107mL plbo grp) & no clear improvements in dyspnea/fatigue/cough But also... 6% absolute reduction in overall, persisted (small n) in https://t.co/Faf26UZuDx
      In the SERENA study (n=292), secukinumab reduced PsA incidence to 0.49/100 PY over 5 years in PsO patients with nail inv

      Antoni Chan MD (Prof) synovialjoints

      1 week 4 days ago
      In the SERENA study (n=292), secukinumab reduced PsA incidence to 0.49/100 PY over 5 years in PsO patients with nail involvement, an ~82% drop vs historic non-biologic rates (2.7/100 PY). 98.3% remained PsA-free; PASI 90 achieved in 63%. Abstract#1463 @RheumNow #ACR25 https://t.co/ySOuFJiwge
      ×